H.C. Wainwright and Leerink Partners Reiterate 'Buy' Ratings on Gossamer Bio, Inc. (GOSS)

With significant hedge fund interest and a share price under $10, Gossamer Bio, Inc. (NASDAQ:GOSS) secures a spot on our list of the 11 Best Single Digit Stocks to Buy According to Hedge Funds.

On August 7, 2025, H.C. Wainwright reiterated its ‘Buy’ rating on Gossamer Bio, Inc. (NASDAQ:GOSS) with a $10 price target. The investment firm highlighted the strong potential of seralutinib, which is an inhaled tyrosine kinase inhibitor that targets vascular remodeling rather than traditional vasodilation.

Furthermore, the analyst noted that the company is well-positioned as its Phase 3 PROSERA trial is fully enrolled, expecting topline results in February 2026. Meanwhile, the SERABATA trial in PH-ILD (pulmonary hypertension associated with interstitial lung disease) is also progressing. At the same time, the analyst applauded the company’s $212.9 million cash position and its strategic partnership with Chiesi, which are boosting investor confidence.

On the previous day, Leerink Partners also maintained its ‘Buy’ rating on Gossamer Bio, Inc. (NASDAQ:GOSS) with a $6 target.

Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, aims to commercialize seralutinib for pulmonary arterial and interstitial lung disease-related hypertension. It is included in our list of the Best Single Digit Stocks.

While we acknowledge the potential of GOSS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Gold Penny Stocks to Buy According to Hedge Funds and 11 Best Rebound Stocks to Buy According to Hedge Funds.

Disclosure: None.